Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

1. CEO Ryan Watts highlighted breakthrough technology and drug pipeline at J.P. Morgan conference. 2. DNL310 aims for 2025 accelerated approval in Hunter Syndrome, crucial for revenue. 3. Estimates show potential over $3 billion value for each franchise in pipeline. 4. Positive progress in DNL126 for Sanfilippo syndrome may speed up development timeline. 5. Strong financial position with $1.28 billion cash runway until 2028 supports growth.